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ture.
Methods: This is a retrospective comparative study between MWA and RFA for hepatocellular
carcinoma (HCC) using surgical approach.
Results: The MWA group consisted of 26 patients while the RFA group consisted of 47 case-
matched patients. The two groups were comparable, except patients were older and their
platelet count was lower in the MWA group. The median follow-up period was 47.5 months
in MWA group and 52.9 months in RFA group (p Z 0.322). There was no difference in 5-year
overall survival (MWA 73.1%, RFA 46.3%, p Z 0.082) and 5-year disease free survival (MWA
13.8%, RFA 14.6%, p Z 0.736). When a subgroup analysis of tumors  3.5 cm was performed,
there were 16 patients in the MWA group and 21 patients in the RFA group, the 5-year overall
and disease-free survival were MWA 75.0%, RFA 28.6% (p Z 0.022) and MWA 25.0%, RFA 4.8%
(p Z 0.207), respectively.ave no conflicts of interest to declare.
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nd/4.0/).1. Introduction
Local ablation therapy is now recognized as a form of
curative treatment for hepatocellular carcinoma (HCC).1e3
Amongst others, two commonly used local ablation thera-
pies are radiofrequency ablation (RFA) and microwave
ablation (MWA).4e7 Initial studies on RFA or MWA for liver
tumors mostly reported on short-term treatment efficacy
such as complete tumor ablation rate and short-term local
recurrence rate while the results of long-term outcomes
are lacking. Furthermore, comparative data on long-term
results between these two techniques are scarce in the
literature. Here we would like to report our experience on
the use of RFA and MWA for HCC by surgical approach (by
laparoscopy or laparotomy) and perform a retrospective
comparative study between them.2. Methods
RFA has been used for ablation of malignant liver tumors in
our institute since 2003. The RFA needle used was either
the cool-tip radiofrequency ablation needle (Covidien,
Fridley, MN, USA) or the LeVeen needle (Boston Scientific,
Natick, MA, USA). The needle was inserted into the tumor
either percutaneously, laparoscopically, or by open lapa-
rotomy. In general, the laparoscopic or open approach was
only adopted when the percutaneous approach was not
feasible due to close proximity of the tumor to hollow
viscera or the diaphragm. The laparoscopic approach again
was considered before the open approach unless the tumor
was difficult for laparoscopic ablations such as tumors
located in the superoposterior segments of the liver or
patients not suitable for laparoscopic procedure. In some
cases, open RFA was done for patients presenting for liver
resection who were found to be unresectable on the
operating table. The initial results of RFA for malignant
liver tumors has been reported previously.8
In 2009, we started a program of MWA for HCC with
funding from a local charity organization. The model of
MWA used was a 2.45-GHz microwave machine (Microsulis
Medical Ltd, Waterlooville, Hants, UK). Because the mi-
crowave antenna supplied at that period was 5 mm in size,
we only applied MWA by laparoscopy or by open laparot-
omy. Again, the laparoscopic approach would always be
considered before the open approach, except in cases when
patients were opened up with the intention for liver
resection but were found to be inoperable on the operating
table.
Between March 2009 and January 2011, 26 consecutive
patients with a diagnosis of HCC were recruited for MWA.
The diagnosis was based on histology or the typical imaginge Kit-fai, et al., Long-term outcom
retrospective comparative studappearance and raised a-fetal protein (AFP) according to
the criteria of the European Association for the Study of
Liver: cirrhotic patients with two images showing focal
lesion > 2 cm with arterial hypervascularization or one
image showing focal lesion > 2 cm with arterial hyper-
vascularization together with AFP > 400 mg/mL. The in-
dications for MWA were: unresectable tumor; resectable
tumor but patient preferred local ablation treatment to
hepatectomy; tumor not feasible for percutaneous RFA;
and no macroscopic vascular or bile duct invasion by the
tumor. We limited the use of MWA to patients with a
maximum of two tumors and size of tumor up to 6 cm.
Recurrent tumor after previous treatment was not consid-
ered a contraindication for MWA. The short-term treatment
outcomes of this group of patients have been reported
previously.9
Between May 2003 and January 2011, a total of 219 pa-
tients underwent RFA treatment for malignant liver tumors
in our institute. To match the patient characteristics of the
MWA group, we only selected patients who underwent RFA
treatment for HCC using surgical approach, with tumors
larger than 2 cm but smaller than 6 cm, and excluded pa-
tients with more than two tumor nodules. Patients with
concomitant hepatectomy were also excluded. Finally,
there were 47 patients in the RFA arm for analysis. Figure 1
shows how the cohort of RFA was generated.
2.1. Ablation techniques
For MWA, the procedure was done in the operating theatre
under general anesthesia. Prophylactic antibiotics were
given as a routine. Any coagulopathy if present was cor-
rected before procedure. If tumor location was favorable,
the tumor would be ablated via the laparoscopic route,
otherwise open laparotomy via a right subcostal incision
with possible upper midline extension was necessary. A
thorough inspection of the peritoneal cavity was performed
to exclude extrahepatic disease. Operative ultrasound
(Aloka, Tokyo, Japan) was used to exclude preoperatively
undetected lesions and to guide insertion of the microwave
applicator. Insertion of the applicator and the whole abla-
tion process was monitored using operative ultrasound.
Surrounding organs were cooled by constant irrigation of
ice-cold saline to prevent thermal injury. The ablation was
carried out according to the standard protocol. The aim was
to create a 1-cm ablation margin around the tumor nodule.
After ablation, the track was burnt and in some cases
packed with a piece of gel-foam to prevent bleeding. With
a single application, MWA could create a maximum ablation
zone of 5 cm  7 cm in 8 minutes.
For RFA using the cool-tip needle, a single needle was
used for small lesions with cluster needles for largeres of microwave versus radiofrequency ablation for hepatocellular
y, Asian Journal of Surgery (2016), http://dx.doi.org/10.1016/
All RFA paƟents 
n = 219
HCC paƟents 
n = 165
Non-HCC paƟents 
n = 54
Percutaneous RFA 
n = 96
Surgical RFA 
n = 69
> 2 tumors 
n = 6
Tumor < 2 cm or > 6 cm 
n = 12
≤ 2 tumors 
n = 63
Tumor 2–6 cm 
n = 51
Concomitant hepatectomy 
n = 4
Without concomitant hepatectomy 
n = 47
excluded 
excluded 
excluded 
excluded 
excluded 
Figure 1 Diagram showing how the cohort of radiofrequency ablation including 47 patients was generated for analysis in this
study. HCC Z hepatocellular carcinoma; RFA Z radiofrequency ablation.
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+ MODELlesions. Each treatment cycle lasted 12 minutes as recom-
mended. For RFA using LeVeen needles, after the tines
were deployed, by using the standard algorithm, the power
was increased stepwise until either the required applica-
tion time had elapsed or the power declined. For both types
of needles, overlapping zones of ablation were made if
needed to ensure adequate coverage of the tumor with a
margin of 1 cm. The needle tract was burnt at the end of
the procedure. For ablation zones, the cool-tip needle
could create a maximum size of 2.5 cm  5 cm with a single
application of clustered needles, while for the LeVeen
needle, the maximum was a spherical 5-cm size using a 5-
cm needle.
Patients receiving MWA or RFA were followed up at
1 month for the first visit, and then every 3 months during
the first 2 years, and every 6 months thereafter. Follow-up
contrast computed tomography (CT) of the abdomen was
performed at 1 month, 3 months, 6 months, and 12 months
postablation, and 6 monthly in the subsequent year and
then yearly thereafter. CT was evaluated by radiologists
experienced in liver tumor ablation. A chest X-ray was
taken every 6 months or if clinically indicated. Serum AFP
was monitored for disease recurrence. In selected cases,
positron emission tomography, bone scan, hepatic angio-
gram, or liver biopsy were performed if recurrence was
suspected. Any intra- or extrahepatic recurrence was
treated accordingly.
All the data were prospectively collected and kept in a
database. The data were censored for analysis in July 2014
for both groups of patients. As a previous study10 on RFA
showed that complete ablation dropped to 50e70% for tu-
mors  3.5 cm, a subgroup analysis was done by stratifyingPlease cite this article in press as: Lee Kit-fai, et al., Long-term outcom
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j.asjsur.2016.01.001tumor size < 3.5 cm and  3.5 cm. Survival was calculated
from the date of MWA or RFA using the KaplaneMeier
method and was compared by the log-rank test. The date of
recurrent disease was dictated by the first imaging study
showing the recurrence. Incomplete ablation was defined
as the presence of residual disease on the first CT scan at
1 month after ablation. For patients with two tumors, both
tumors were taken for determination of treatment effect.
Ablation was only considered completed if both ablation
sites showed no residual tumors on the first CT scan post-
operatively. Any subsequent development of the disease
after initial complete ablation was regarded as recurrence.
Local recurrence was defined as disease occurring adjacent
to previous ablation sites while remote recurrence was
defined as those recurrences occurring distant to previous
ablation sites. Multifocal recurrence was defined as multi-
ple intrahepatic recurrent tumors away from the ablation
site. Fisher exact test was used for comparison of cate-
gorical variables. A p-value < 0.05 was considered statis-
tically significant.3. Results
There were 26 patients in the MWA group and 47 in the RFA
group. Eight patients (31%) in the MWA group and 21 pa-
tients (44%) in RFA group were offered liver resection.
There was no significant difference between the two groups
(p Z 0.245). Liver resection was not performed due to
small liver remnant or unfavorable tumor location during
exploration. One patient in each group refused liver
resection but agreed to local ablation only. The rest werees of microwave versus radiofrequency ablation for hepatocellular
y, Asian Journal of Surgery (2016), http://dx.doi.org/10.1016/
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+ MODELnot offered liver resection due to either poor liver reserve
or coexisting medical condition. The patient demographics,
tumor characteristics, and perioperative outcomes are
shown in Table 1. The two groups were comparable except
patients were older and platelet count was lower in the
MWA group. The number and size of tumors did not differ
between the two groups. The median tumor size was
3.75 cm in the MWA group and 3.1 cm in the RFA group. The
laparoscopic approach was used more in the MWA group
while more concomitant procedures, which were mostly
cholecystectomy, were done in the RFA group. The opera-
tive time was significantly greater in the RFA group. There
was no 30-day mortality in this study. There were no dif-
ferences in complication rate and postoperative hospital
stay. Six complications occurred in four patients in the MWA
group: chest infection; adult respiratory distress syndrome;
atrial fibrillation; hand cellulitis; skin bruising; and intra-
abdominal collection. Nineteen complications occurred in
16 patients in the RFA group: four pleural effusions; threeTable 1 Patient demographics and perioperative outcomes.
MWA (n Z
Age (y) 62.5 (49e
Male 19 (73.
No. of comorbidities 1 (0e4
HBsAg þ 21 (80.
Child’s grading
A 23 (88.
B 3 (11.
a-fetal protein (mg/L) 13.5 (1e2
Platelet (109/L) 92.5 (25e
Albumin (g/L) 39.5 (30e
Bilirubin (mM) 17 (4e3
INR 1.125 (0.9
ALP (IU/L) 108 (6e2
Recurrent HCC 5 (19.
No. of lesions
Solitary 24 (92.
Two lesions 2 (7.7
Tumor size (cm) 3.75 (2.0
Tumor > 5 cm 3 (11.
Approach
Open 10 (38.
Laparoscopic 15 (57.
Laparoscopic converted to open 1 (3.8
Concomitant procedure 2 (7.7
Types of concomitant procedure
Cholecystectomy only 1 (3.8
Colectomy 0 (0%)
Cholecystectomy and excision of pelvic tumor 1 (3.8
Hernia repair 0 (0.0
Operative time (min) 117.5 (65e
30-d mortality 0 (0.0
Reoperation rate 0 (0.0
Complication rate 4 (15.
Postop hospital stay 6 (2e1
* Statistically significant p < 0.05.
ALP Z alkaline phosphatase; HBsAgþ Z hepatitis B surface antigen
standardized ratio; MVA Z microwave ablation; NA Z not applicable
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j.asjsur.2016.01.001wound complications; two chest infections; two atrial fi-
brillations; two ascites; one lung collapse; one liver ab-
scess; one subphrenic collection; one supraventricular
tachycardia; one deep vein thrombosis; and one acute
retention of urine. Of note, there were no biliary or
vascular complications in either group.
The long-term outcomes, recurrent diseases, and sur-
vival data are shown in Table 2. The incidence of residual
disease was 3.8% and 6.4% in MWA and RFA groups,
respectively. For the 4 patients who had residual tumors,
two received percutaneous RFA and two received trans-
catheter arterial chemoembolization. The follow-up period
was 47.5 (11.3e62.5) months in the MWA group and 52.9
(3.6e121.8) months in the RFA group (p Z 0.322).The
overall disease recurrence rate was 80.8% in MWA and 83.0%
in RFA. There was no difference between the two groups in
incidence of local recurrence, remote recurrence, multi-
focal recurrence, or extrahepatic recurrence. Two patients
in the MWA group and six patients in the RFA group were26) RFA (n Z 47) p
79) 58 (43e77) 0.033*
1%) 40 (85.1%) 0.230
) 1 (0e5) 0.538
8%) 39 (83.0%) > 0.999
5%) 42 (89.4%) > 0.999
5%) 5 (10.6%)
3,956) 25 (2e10,174) 0.310
265) 127 (41e250) 0.019*
47) 39 (14e77) 0.380
7) 13 (6e61) 0.294
8e1.42) 1.120 (0.99e1.53) 0.699
29) 90 (50e195) 0.895
2%) 4 (8.5%) 0.266
3%) 42 (89.4%) > 0.999
%) 5 (10.6%)
e6.0) 3.1 (2.0e6.0) 0.066
5%) 2 (4.3%) 0.340
5%) 35 (74.5%) 0.002*
7%) 9 (19.1%)
%) 3 (6.4%)
%) 28 (59.6%) < 0.001*
%) 26 (55.3%)
1 (2.1%)
%) 0 (0%)
%) 1 (2.1%)
250) 195 (93e480) < 0.001*
%) 0 (0.0%) NA
%) 1 (2.1%) (wound disruption) > 0.999
4%) 16 (34.0%) 0.087
3) 6 (2e16) 0.102
positive; HCC Z hepatocellular carcinoma; INR Z international
; RFA Z radiofrequency ablation.
es of microwave versus radiofrequency ablation for hepatocellular
y, Asian Journal of Surgery (2016), http://dx.doi.org/10.1016/
Table 2 Long-term outcomes after ablation.
MWA
(n Z 26)
RFA
(n Z 47)
p
Follow-up period (mo) 47.5
(11.3e62.5)
52.9
(3.6e121.8)
0.322
Residual disease 1 (3.8%) 3 (6.4%) > 0.999
Overall recurrence rate 21 (80.8%) 39 (83.0%) > 0.999
Intrahepatic recurrence 21 (80.8%) 39 (83.0%) > 0.999
Local recurrence 6 (23.1%) 12 (25.5%) 0.816
Remote recurrence 7 (26.9%) 15 (31.9%) 0.656
Multifocal recurrence 8 (30.8%) 12 (25.5%) 0.631
Extrahepatic recurrence 2 (7.7%) 10 (21.3%) 0.192
Overall survival
1-y survival 96.2% 89.4% 0.299
3-y survival 73.1% 61.7% 0.218
5-y survival 73.1% 46.3% 0.081
Disease-free survival
1-y survival 57.7% 68.1% 0.439
3-y survival 34.6% 23.4% 0.594
5-y survival 13.8% 14.6% 0.736
MVA Z microwave ablation; RFA Z radiofrequency ablation.
Figure 2 Log-rank test showed no difference between the
two groups in overall and disease-free survival. (A) Log-rank
test: p Z 0.082. (B) Log-rank test: p Z 0.736.
RFA Z radiofrequency ablation.
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was no significant difference in prescription of the drug
between the two groups (p Z 0.703). The 5-year overall
and disease-free survival for MWA were 73.1% and 13.8%
respectively. The 5-year overall and disease-free survival
for RFA were 46.3% and 14.6% respectively. Figure 2 shows
that there was no difference between the two groups in
overall and disease-free survival by log-rank test (pZ 0.082
and 0.736, respectively).
When analysis was made on subgroups according to
tumor size < 3.5 cm and  3.5 cm, the long-term outcomes
are shown in Tables 3 and 4 and the survival in Figures 3 and
4. For tumors < 3.5 cm, there were 10 patients in the MWA
group and 26 patients in the RFA group. The 5-year overall
and disease-free survival for MWA were 70.0% and 0.0%,
respectively, while the 5-year overall and disease-free
survival for RFA were 61.1% and 22.4%, respectively.
Figure 3 shows that there was no difference between the
two groups in overall and disease free survival by log-rank
test (p Z 0.732 and 0.639, respectively).
For tumors  3.5 cm, there were 16 patients in the MWA
group and 21 patients in the RFA group. The 5-year overall
and disease-free survival for MWA were 75.0% and 25.0%,
respectively, while the 5-year overall and disease survival
for RFA were 28.6% and 4.8%, respectively. By log-rank test
(Figure 4) there was a significant difference in overall sur-
vival favoring MWA (pZ 0.022) but there was no difference
in disease-free survival (p Z 0.207).4. Discussion
Both RFA and MWA have gained wide acceptance as reliable
thermal ablation treatments for malignant liver tumors.
Studies have reported high complete ablation rates and low
local recurrence rates. The complete ablation rate is
closely related to tumor size. For RFA, the rates ofPlease cite this article in press as: Lee Kit-fai, et al., Long-term outcom
carcinoma by surgical approach: A retrospective comparative stud
j.asjsur.2016.01.001complete ablation were 90%, 70e90%, 50e70%, and < 50%
for HCC of size < 2.5 cm, 2.5e3.5 cm, 3.5e5 cm, and
> 5 cm, respectively.10 For MWA, the rates of complete
ablation were 92% and 80e95% for tumors < 2 cm and
> 2 cm, respectively.11,12 However, data were difficult to
interpret due to different ways of applying ablation:
percutaneous, laparoscopic, or via laparotomy. Further-
more, results would be affected by the pathology of the
liver tumor treated, mostly HCC or colorectal liver metas-
tasis. Finally, as different types of commercially available
models of RFA and MWA machines are present in the mar-
ket, the efficacy of the machine may also be different.
Even within the MWA category, two types of frequency are
commonly used (915 MHz and 2.45 GHz) which may differ in
clinical efficacy.13 In the present study we tried to confine
our study disease to HCC only with either laparoscopic or
open approach, although we did employ two different
brands of RFA machine during the study period. The medianes of microwave versus radiofrequency ablation for hepatocellular
y, Asian Journal of Surgery (2016), http://dx.doi.org/10.1016/
Table 3 Long-term outcomes after ablation for tumors
< 3.5 cm.
MWA
(n Z 10)
RFA
(n Z 26)
p
Overall recurrence rate 9 (90.0%) 19 (73.1%) 0.397
Intrahepatic recurrence 9 (90.0%) 19 (73.1%) 0.397
Local recurrence 2 (20.0%) 5 (19.2%) > 0.999
Remote recurrence 4 (40.0%) 9 (34.6%) > 0.999
Multifocal recurrence 3 (30.0%) 5 (19.2%) 0.658
Extrahepatic recurrence 2 (20.0%) 3 (11.5%) 0.603
Overall survival
1-y survival 90.0% 92.3% 0.856
3-y survival 70.0% 73.1% 0.961
5-y survival 70.0% 61.1% 0.736
Disease-free survival
1-y survival 60.0% 76.9% 0.386
3-y survival 50.0% 38.5% 0.801
5-y survival 0.0%. 22.4% 0.639
MVA Z microwave ablation; RFA Z radiofrequency ablation.
Table 4 Long-term outcomes after ablation for tumors
 3.5 cm.
MWA
(n Z 16)
RFA
(n Z 21)
p
Overall recurrence rate 12 (75.0%) 20 (95.2%) 0.144
Intrahepatic recurrence 12 (75.0%) 20 (95.2%) 0.144
Local recurrence 4 (25.0%) 7 (33.3%) 0.723
Remote recurrence 3 (18.8%) 6 (28.6%) 0.702
Multifocal recurrence 5 (31.3%) 7 (33.3%) 0.893
Extrahepatic recurrence 0 (0.0%) 7 (33.3%) 0.012*
Overall survival
1-y survival 100% 85.7% 0.121
3-y survival 75.0% 47.6% 0.102
5-y survival 75.0% 28.6% 0.022*
Disease-free survival
1-y survival 56.3% 57.1% 0.987
3-y survival 25.0% 4.8% 0.207
5-y survival 25.0% 4.8% 0.207
* Statistically significant p < 0.05.
MVA Z microwave ablation; RFA Z radiofrequency ablation.
Figure 3 Log-rank test for tumors < 3.5 cm showed no dif-
ference between the two groups in overall and disease free
survival. (A) Log-rank test: p Z 0.732. (B) Log-rank test:
p Z 0.639. RFA Z radiofrequency ablation.
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+ MODELfollow-up periods of at least 4 years can provide us more
valid information on the treatment outcomes in the long
term.
For the short-term outcomes in this study, both MWA and
RFA yielded similar results in procedure related morbidity
and hospital stay, and both had no mortality. The rate of
residual disease was 3.8% in MWA and 6.4% in RFA, which
was not statistically different. Despite matching, the pa-
tients in the MWA group in this study were significantly
older and had a lower platelet count than the RFA group.
Although the tumor size was similar, the median size in the
MWA group was 3.75 cm in comparison to 3.1 cm in the RFA
group, and the open approach was employed more in the
RFA group. It appears that MWA bears more unfavorable
factors, but achieved similar treatment outcomes as RFA.Please cite this article in press as: Lee Kit-fai, et al., Long-term outcom
carcinoma by surgical approach: A retrospective comparative stud
j.asjsur.2016.01.001Several studies have addressed the long-term outcomes
of RFA or MWA for malignant liver tumors. In the study by
Peng et al,14 224 patients with HCC of median size of 2.5 cm
received RFA as primary treatment. The overall 5-year and
10-year survival was 59.8% and 33.9%, respectively. The
tumor free 5-year and 10-year survival was 42.4% and
28.2%, respectively. In a more recent study on RFA for HCC
of mean tumor size of 2.59 cm, the overall 5-year survival
was 67.9% and the 5-year recurrence-free survival was
25.9%.15 By contrast, a study on long-term outcomes of
MWA for malignant liver tumors, mostly colorectal liver
metastases, revealed a 4-year overall survival of 57.6%.16 In
the study by Takami et al,17 MWA was offered as initial
treatment for 719 patients with HCC of median size
2.69 cm, the 5-year and 10-year overall survival was 62.1%
and 34.1%, respectively, while the 5-year and 10-year
disease-free survival was 31.0% and 16.5%, respectively.
Most of the studies in the literature comparing MWA and
RFA for HCC utilized the percutaneous route.10,18e22 Alles of microwave versus radiofrequency ablation for hepatocellular
y, Asian Journal of Surgery (2016), http://dx.doi.org/10.1016/
Figure 4 Log-rank test showing significant difference in
overall survival favoring microwave ablation, however, there
was no difference in disease-free survival for tumors  3.5 cm.
(A) Log-rank test: p Z 0.022*. (B) Log-rank test: p Z 0.207.
RFA Z radiofrequency ablation.
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+ MODELstudies except one showed that the two ablation modalities
produced equivalent clinical efficacy in terms of ablation
rates, complication rates, and survival rates. The study that
showed a difference favored RFA because it achieved a
lower local recurrence rate, higher survival rate, and more
extensive necrosis with fewer treatment sessions.19 How-
ever, that study only involved patients with small
HCC  2 cm in size. One study compared laparoscopic-
assisted MWA with laparoscopic-assisted RFA for HCC.23 It
involved 13 patients with 15 tumors in the MWA group and
22 patients with 27 tumors in the RFA group. It was found
that laparoscopic MWA achieved outcomes similar to lapa-
roscopic RFA, but MWA carried shorter operative times.
In the current study, with sufficient follow up, recurrent
diseases were found in 80.8% and 83% of patients after MWA
and RFA, respectively. There was no difference in the inci-
dence of different types of recurrence between the two
groups. The local recurrence rates were 23.1% and 25.5% forPlease cite this article in press as: Lee Kit-fai, et al., Long-term outcom
carcinoma by surgical approach: A retrospective comparative stud
j.asjsur.2016.01.001MWA and RFA, respectively. These were comparable to other
studies becausemost of the previous studies involved shorter
follow up (2e3 years) for smaller tumor sizes of 2e3 cm with
reported local recurrence rate ranging from 2% to 20%.5,10,16
The overall 5-year survival was better inMWA than RFA (73.1%
vs. 46.3%) but was not statistically different. The better 5-
year overall survival, but not the disease-free survival, in
the MWA group (although not statistically significant) may be
due to better local control of disease by MWA, which was
more amendable for retreatment despite recurrence, or due
to more effective treatments for recurrent disease, because
patients receiving MWA were concentrated in the later
period, during which advances in treatment technology such
as transarterial therapy, repeat local ablation, or even hep-
atectomy may prolong survival. The difference became sig-
nificant when only larger tumors,  3.5 cm, were compared
(p Z 0.022). However, the 5-year disease-free survival was
similar even when only larger tumors were studied. The dif-
ferencemaybe explained by the larger ablation zone created
with single application of MWA. RFA needs multiple applica-
tions at overlapping sites to create a similar ablation zone.
Any malposition of the needle results in microscopic residual
disease that gives rise to recurrence. Less heat sink effect
with MWA might also account for more successful complete
ablation for perivascular tumors.24
Apparently, within the MWA group, the 5-year overall
and disease-free survival were better for tumors  3.5 cm
compared with tumors < 3.5 cm. However, when we per-
formed the survival analysis for tumors < 3.5 cm versus
 3.5 cm using microwave treatment, the p-value of the
log-rank test for overall survival was 0.846, and for disease-
free survival was 0.964, therefore, there was no significant
difference between the two. When we looked in detail for
other factors that might affect the ablation result, we
found that the open approach was adopted significantly
more often than laparoscopic approach in patients with
larger tumors (n Z 10, 62.5% vs. n Z 1, 10%; p Z 0.014).
The open approach might make insertion of the microwave
applicator more precise and ablation more complete.
Thereare several drawbacksand limitations to thepresent
study. The diagnosis of HCC was not histologically proven in
every patient and therefore there is a chance of over-
estimation of treatment response. The patient number is
small, hence difference in outcomes may not show up on
comparative analysis. For the RFA arm, two types of machine
were used,whichmayhave affected the treatment outcomes
for RFA. Finally, the difference in experience in usage of the
ablative tool may also have directly affected the treatment
result. Our institute is currently conducting a prospective
randomized trial of MWA versus RFA for HCC patients, and
hopefully results will be available in a few years’ time.5. Conclusion
MWA provides similar short- and long-term treatment out-
comes as compared with RFA for HCC using laparotomy or
the laparoscopic approach. However, MWA seems to convey
a better 5-year overall survival for tumors  3.5 cm in size.
A prospective randomized trial of MWA versus RFA involving
a larger study population is warranted to verify the finding
of this retrospective study.es of microwave versus radiofrequency ablation for hepatocellular
y, Asian Journal of Surgery (2016), http://dx.doi.org/10.1016/
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